Handelsavisen
prelaunch
Companies ›Healthcare ›CRDL.TO
CR
CRDL.TO — Toronto Stock Exchange Biotechnology & Medical Research

Cardiol Therapeutics Inc

C$1,48
Open in Charts → Attach watcher ⌖
— —
CAD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
-189,2 %
Net margin
—
Debt / equity
0,01
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

Cardiol Therapeutics Inc is a biotechnology company focused on the development of novel therapeutics for the treatment of cardiovascular diseases, primarily through the advancement of cardiolipin-based drug candidates.

Business. Cardiol Therapeutics Inc (CRDL.TO) is a biotechnology and medical research company operating within the healthcare diagnostics industry. The firm is headquartered in Canada and is primarily listed on the Toronto Stock Exchange. As no specific operating segments or geographic breakdowns are provided, the company is described at the industry level.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
BUY3 analysts
3 buy0 hold0 sell
Avg 12m price target8,49

Analyst recommendations

3 analysts · consensus Buy
Buy3
Hold0
Sell0
12-month price target
8,49
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
3 analysts · indicative
Ownership→
Goldman Sachs Asset Management, L.P.
largest disclosed fund holder
Profitability→
-189,2 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning CRDL.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to CRDL.TO. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Cardiol Therapeutics Inc (CRDL.TO) is a biotechnology and medical research company operating within the healthcare diagnostics industry. The firm is headquartered in Canada and is primarily listed on the Toronto Stock Exchange. As no specific operating segments or geographic breakdowns are provided, the company is described at the industry level.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityHealthcare Diagnostics
    AI synthesis
    GENERATED

    Cardiol Therapeutics Inc maintains a strong liquidity position, with cash and equivalents amounting to CAD 21.42 million, which significantly exceeds its total liabilities of CAD 5.74 million, resulting in a current ratio of 4.16. The company's debt-to-equity ratio is 0.01, indicating minimal leverage and a conservative capital structure.

    The company's profitability remains negative, with a net loss of CAD 33.82 million and an operating loss of CAD 34.32 million in the latest reporting period. Return on equity is -189.17%, and return on assets is -143.18%, both of which are well below the typical performance metrics for the biotechnology industry. These figures suggest that the company is not currently generating returns for shareholders or effectively utilizing its assets.

    Cardiol Therapeutics Inc operates as a single-segment entity, with no disclosed geographic revenue concentration. The company's operations are primarily focused on research and development, with no material revenue streams from product sales or licensing agreements. This lack of diversification increases the company's exposure to R&D risks and regulatory delays.

    The company's growth trajectory is not yet defined in terms of revenue, as it has not reported any revenue in the latest financial period. Looking ahead, the company is expected to remain in a development phase, with no immediate revenue generation anticipated. The absence of revenue and continued losses suggest that the company is in the early stages of commercialization.

    Risk factors for Cardiol Therapeutics Inc include the high costs and uncertainties associated with drug development, regulatory approval delays, and the competitive landscape in the biotechnology sector. The company has not disclosed any immediate dilution risks, and its dilution potential is currently assessed as low. However, the company may need to raise additional capital to fund ongoing operations, which could result in future share dilution.

    Recent events include the continued development of the company's lead candidate, CDL-001, which is in clinical trials for the treatment of atrial fibrillation. The company has also engaged in strategic partnerships to advance its pipeline. No recent filings or transcripts indicate significant changes in the company's strategic direction or financial outlook.

    Key takeaways
    • Cardiol Therapeutics Inc has a strong liquidity position with CAD 21.42 million in cash and equivalents.
    • The company is currently unprofitable, with a net loss of CAD 33.82 million and a return on equity of -189.17%.
    • The company operates as a single-segment entity with no geographic revenue diversification.
    • The company is in the early stages of commercialization and has not yet generated revenue.
    • The company's risk profile is moderate, with low liquidity and dilution risks but high R&D and regulatory risks.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    C$1,48
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    C$17.9M
    Net cashⓘ
    C$21.3M
    Current ratioⓘ
    4.2
    Debt / equityⓘ
    0.0
    ROAⓘ
    -1.4%
    ROEⓘ
    -1.9%
    Cash conversionⓘ
    71.0%
    CapEx / revenueⓘ
    —
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -0,57
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    3
    Other metrics
    Revenue
    —
    no estimate
    Segment revenue
    —
    no estimate
    Margin
    —
    no estimate
    Segment margin
    —
    no estimate
    as of 2026-05-15 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPS—no estimate—no estimate-0,57
    Revenue—no estimate—no estimate0 CAD
    Operating income—no estimate—no estimate-33,0M CAD
    Full-year consensus mean (period as reported by source) · consensus in CAD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution3 analysts
    Strong buy0
    Buy3
    Hold0
    Sell0
    Strong sell0
    12-month price targetC$8,49 · Median C$7,50
    Low C$6,96High C$11,00
    Operating income · consensus-33,0M CAD
    EPS surprise
    +32,0 %
    reported vs consensus · beat

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    LowC$6,96
    MeanC$8,49
    MedianC$7,50
    HighC$11,00
    SpotC$1,48
    +473.4 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    ROE-189,2 %Bottom quartile
    D/E0,01Above median
    Cash Conv0,71Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Return On Assets
      net_income / total_assets
    Source documents
    • Cardiol Therapeutics Inc Market data — financials · 2026-05-27
    • Cardiol Therapeutics Inc Market data — analyst estimates · 2026-05-27

    Ownership & reference

    Top holders

    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$0M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$0M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M

    Leadership

    • David ElsleyPresident, Chief Executive Officer, Director

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    CRDL.TOCanonical
    Toronto Stock Exchange · CAD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage